A detailed history of Jpmorgan Chase & CO transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 71 shares of SPRB stock, worth $27. This represents 0.0% of its overall portfolio holdings.

Number of Shares
71
Previous 72 1.39%
Holding current value
$27
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$0.42 - $0.59 $0 - $0
-1 Reduced 1.39%
71 $0
Q2 2024

Aug 12, 2024

BUY
$0.51 - $0.85 $31 - $51
61 Added 554.55%
72 $0
Q3 2023

Nov 14, 2023

SELL
$2.04 - $2.54 $48,039 - $59,814
-23,549 Reduced 99.95%
11 $0
Q2 2023

Aug 11, 2023

SELL
$1.92 - $2.6 $66,468 - $90,009
-34,619 Reduced 59.5%
23,560 $50,000
Q1 2023

May 11, 2023

BUY
$1.15 - $3.17 $66,893 - $184,392
58,168 Added 528800.0%
58,179 $128,000
Q2 2022

Aug 11, 2022

SELL
$1.28 - $2.23 $145,113 - $252,815
-113,370 Reduced 99.99%
11 $0
Q1 2022

May 11, 2022

SELL
$1.85 - $4.59 $9,224 - $22,885
-4,986 Reduced 4.21%
113,381 $227,000
Q4 2021

Feb 10, 2022

SELL
$2.33 - $5.74 $16,524 - $40,708
-7,092 Reduced 5.65%
118,367 $528,000
Q3 2021

Nov 12, 2021

BUY
$6.01 - $11.26 $754,008 - $1.41 Million
125,459 New
125,459 $754,000

Others Institutions Holding SPRB

About SPRUCE BIOSCIENCES, INC.


  • Ticker SPRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,560,200
  • Market Cap $9.19M
  • Description
  • Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...
More about SPRB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.